Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
| ▸ | GABRE | P78334 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23411245 | 1.00 | LMNA (0.46) | LMNAMAPTTP53GLAGAA | |
| SCHEMBL23410848 | 0.89 | TP53 (0.43) | LMNAMAPTTP53POLBALDH1A1 | |
| SCHEMBL29890670 | 0.89 | TP53 (0.43) | LMNAMAPTTP53POLBALDH1A1 | |
| SCHEMBL23410658 | 0.89 | LMNA (0.41) | LMNAMAPTTP53GLAGAA | |
| SCHEMBL29890195 | 0.88 | LMNA (0.48) | LMNAMAPTTP53HSD17B10POLB | |
| SCHEMBL23410883 | 0.88 | LMNA (0.48) | LMNAMAPTTP53HSD17B10POLB | |
| SCHEMBL29890887 | 0.87 | HDAC6 (0.39) | LMNATP53HSD17B10POLBSMN1; SMN2 | |
| SCHEMBL23410934 | 0.87 | HDAC6 (0.39) | LMNATP53HSD17B10POLBSMN1; SMN2 | |
| SCHEMBL23410720 | 0.87 | SMN1; SMN2 (0.43) | LMNAMAPTTP53HSD17B10POLB | |
| SCHEMBL29890509 | 0.87 | SMN1; SMN2 (0.43) | LMNAMAPTTP53HSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661869-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4661870-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | claimed |
| CN-119523983-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-28 | — | — | CN | claimed |
| CN-119424429-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-14 | — | — | CN | claimed |
| CN-115003665-B | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2024-11-08 | — | — | CN | claimed |
| WO-2024165470-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-15 | — | — | WO | claimed |
| WO-2024165469-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-15 | — | — | WO | claimed |
| EP-4065574-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2022-10-05 | — | — | EP | claimed |
| CN-115003665-A | Substituted aminoquinolones as immunoactive DGK alpha inhibitors | 拜耳公司 | 2022-09-02 | — | — | CN | claimed |
| EP-4661906-A1 | COMBINATION OF CCR8 ANTIBODIES WITH DGK INHIBITORS IN THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4661870-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4661869-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | disclosed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| WO-2024165470-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024165468-A1 | COMBINATION OF CCR8 ANTIBODIES WITH DGK INHIBITORS IN THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024165469-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-15 | — | — | WO | disclosed |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | LMNA 1953/4885MAPT 4812/4885TP53 1307/4885 |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | DGKK, DGKG, DGKA | LMNA 1953/4885MAPT 4812/4885TP53 1307/4885 |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | LMNA 1953/4885MAPT 4812/4885TP53 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.